Publications by authors named "Elke Sylvester"
Article Synopsis
- * The treatment involves two oral cycles each year for two years, potentially eliminating the need for further doses in the following years, making it a convenient option for patients with relapsing forms of MS.
- * Clinical studies, including the significant phase III CLARITY trial, demonstrated the efficacy and safety of cladribine tablets, leading to global approval for the treatment of various types of relapsing MS.
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. Safety and tolerability outcomes from individual clinical studies with cladribine tablets have been reported previously.
Objective: Report safety data from an integrated analysis of clinical trials and follow-up in patients with MS to further characterize the safety profile of cladribine tablets.